Disclaimer: The following content discusses our Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by our FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath-enabled TAMP with gemcitabine for the treatment of locally advanced pancreatic cancer (LAPC) is being studied under an IND. This combination product candidate has not been approved by FDA for commercial use and its safety and effectiveness in treating LAPC has not been established. For RenovoCath’s Indications for Use and safety information, please visit IFU-10004-Rev.-G-Universal-IFU.pdf.

Doctors Testing 'Groundbreaking' Treatment for Pancreatic Cancer

Released June 2, 2021

CHARLOTTE, N.C. — A new treatment for pancreatic cancer is being tested out in clinical trials in several states, and one North Carolina doctor called it “groundbreaking.”

The trials are being conducted in multiple cities across the country, including in North Carolina, California, New York, Florida and others along the East and West coasts.

View the entire article and watch the video on Spectrum News 1

RenovoRx is participating in clinical trials and the FDA has not determined the safety and or efficacy of its clinical drug development program.